Early-onset epileptic encephalopathies and the diagnostic approach to underlying causes

Article information

Korean J Pediatr. 2015;58(11):407-414

Publication date (electronic) : 2015 November 22

doi : https://doi.org/10.3345/kjp.2015.58.11.407

Su-Kyeong Hwang, MD, PhD , Soonhak Kwon, MD

Department of Pediatrics, Kyungpook National University Children's Hospital, Daegu, Korea.

Corresponding author: Soonhak Kwon, MD. Department of Pediatrics, Kyungpook National University Children's Hospital, 807 Hoguk-ro, Bukku, Daegu 41404, Korea. Tel: +82-53-200-2746, Fax: +82-53-425-6683, shkwon@knu.ac.kr

Received 2015 September 01; Accepted 2015 October 28.

Abstract

Early-onset epileptic encephalopathies are one of the most severe early onset epilepsies that can lead to progressive psychomotor impairment. These syndromes result from identifiable primary causes, such as structural, neurodegenerative, metabolic, or genetic defects, and an increasing number of novel genetic causes continue to be uncovered. A typical diagnostic approach includes documentation of anamnesis, determination of seizure semiology, electroencephalography, and neuroimaging. If primary biochemical investigations exclude precipitating conditions, a trial with the administration of a vitaminic compound (pyridoxine, pyridoxal-5-phosphate, or folinic acid) can then be initiated regardless of presumptive seizure causes. Patients with unclear etiologies should be considered for a further workup, which should include an evaluation for inherited metabolic defects and genetic analyses. Targeted next-generation sequencing panels showed a high diagnostic yield in patients with epileptic encephalopathy. Mutations associated with the emergence of epileptic encephalopathies can be identified in a targeted fashion by sequencing the most likely candidate genes. Next-generation sequencing technologies offer hope to a large number of patients with cryptogenic encephalopathies and will eventually lead to new therapeutic strategies and more favorable long-term outcomes.

Keywords: Epileptic encephalopathy; Early infantile; Genetics; Mutation; High throughput nucleotide sequencing

Introduction

Early-onset epileptic encephalopathies (EOEE) are one of the most devastating early onset epilepsies that contribute to progressive decline of cerebral function1). Most patients show the three main features of EOEE: refractory seizures, severe electroencephalographic abnormalities, and developmental delay or intellectual disability2). A tendency to be refractory to antiepileptic drugs often leads to severe cognitive and behavioral impairment3). Identifiable primary causes, such as known structural, neurodegenerative, metabolic, genetic, or chromosomal disorders, and an increasing number of novel genetic causes are being identified in EOEE3 4). The most common causes are structural brain abnormalities and inborn metabolic defects5). If neuroimaging and biochemical examinations exclude common etiologies, the remaining fraction, comprising about one third of all EOEE cases, represents cryptogenic cases, where genetic factors are considered to have an important role6 7). EOEE is a genetically heterogeneous disorder: over 100 genes have been suggested to be involved in the etiology of these syndromes8). Many EOEE cases are sporadic, occurring in patients with no family history of seizures or epilepsies9). Sporadic cases are commonly caused by autosomal dominant de novo mutations in genes encoding neuronal proteins. EOEE can also be inherited in an autosomal recessive or X-linked manner. Next-generation sequencing (NGS) technology has revolutionized our ability to sequence DNA at the whole exome or whole genome level at an increasingly affordable price10). Whole exome sequencing now costs under $1,000 per sample and numerous studies have successfully identified de novo mutations in individuals with various neurodevelopmental disorders11 12). In epilepsy genetics, the focus has been almost exclusively on genes encoding membrane ion channel proteins. However, an increasing number of mutations in genes encoding proteins other than ion channels are now being identified by NGS2). Epi4k, the international consortium for advanced genetic studies of epilepsy, has been making significant progress in epilepsy genetics by using NGS. The consortium was launched in 2011 in response to a National Institute of Neurological Disorders and Stroke (NINDS) Funding Opportunity Announcement soliciting applications for "Centers Without Walls for Collaborative Research in the Epilepsies: Genetics and Genomics of Human Epilepsies" and adopted the name "Epi4K: Gene Discovery in 4000 Genomes"10 13). The first project of Epi4K focused on the discovery of de novo mutations in Lennox-Gastaut syndrome and infantile spasms. Over 300 de novo mutations in genes including SCN1A, STXBP1, SCN8A, SCN2A, CDKL5, GABRB3, ALG13, CACNA1A, CHD2, FLNA, GABRA1, GRIN1, GRIN2B, HNRNPU, IQSEC2, MTOR, and NEDD4L have been discovered. Statistical evidence of association between epileptic encephalopathy and mutations in GABRB3 and ALG13 was also identified9 10). In this article, we will focus on the diagnostic strategies for EOEE, especially on NGS-based genetic analysis for cryptogenic EOEE cases.

Epileptic encephalopathy syndromes in infancy

1. Vitamin-responsive epileptic encephalopathies

Vitamin-responsive epileptic encephalopathies are rare but important causes of EOEE. They commonly result in refractory seizures with poor neurocognitive outcomes if specific treatment is delayed. The type of seizures, etiologies, and treatments are summarized in Table 1. If seizures persist despite the use of two or more appropriate anticonvulsants at maximum tolerated doses, then add-on vitamin treatment should be considered. Pyridoxine-dependent epilepsy (PDE) and pyridoxal-5-phosphate-dependent epilepsy share similar clinical presentations as pyridoxal-5-phosphate is derived from pyridoxine14). In the early onset type, patients will typically develop abnormal movements soon after birth and electroencephalogram (EEG) can be either completely normal or exhibit a burst suppression pattern15). Prognosis is generally good with prompt treatment, but death or significant intellectual and motor disability may occur if treatment is delayed16). Pyridoxal-5-phosphate may be used as an initial treatment, which would be effective against both PDE and pyridoxal-5-phosphate dependent epilepsy. Pyridoxine could be introduced later, replacing pyridoxal-5-phosphate as a cheaper and similarly effective alternative, if PDE diagnosis is confirmed17). Folinic acid responsive epilepsies are caused by low concentration of 5-methyltetrahydrofolate (MTHF) in the cerebrospinal fluid (CSF), which is associated with various neurological conditions18). Genetic or autoimmune mechanisms cause cerebral folate deficiency and delayed treatment may lead to encephalopathy with severe learning disabilities. EEG may show abnormal background activity with multifocal spike-wave complexes, but typically has no diagnostic features. Neuroimaging results are also usually normal19). Patients either do not respond to pyridoxine at all or exhibit only a temporary improvement. However, such patients show a marked neurological recovery including cessation of seizures upon folinic acid treatment18). Biotinidase deficiency is a biotin-responsive metabolic disorder causing impairment of functions of multiple carboxylases and presenting with seizures, hypotonia, visual/auditory symptoms, eczema, and alopecia. Untreated children usually have neurocutaneous features between the ages of 2 and 5 months18 20). Seventy percent of patients have various type of seizures including infantile spasms21). Seizures and other symptoms improve often within a day of treatment with biotin. It has been suggested that similarly to pyridoxine trials, biotin treatment should be considered in any child with poorly controlled seizures22). Regardless of age or weight, a dose of 5- to 20-mg biotin daily has been found to be effective and needs to be continued for the rest of patient's life if it offers stable improvement23 24). Vitamin B12 deficiency may lead to various neurologic symptoms including developmental delay or regression, irritability, weakness, hypotonia, and convulsions. Seizures are a rare presentation of vitamin B12 deficiency but they have been occasionally reported, especially in infants, including cases of West syndrome25 26). Vitamin B12 deficiency caused by dietary preferences of mothers, who may be vegan, is the most common cause of such symptoms in breast-fed infants between 4 and 8 months, even when the mothers exhibit no hematological or neurological symptoms themselves26 27). Serum levels of methylmalonic acid and total homocysteine have been shown to be markedly elevated in the majority of such patients. Vitamin B12 deficiency should be considered in all infants with developmental delay, hypotonia, or seizures for whom an alternate diagnosis cannot be made.

Table 1

Summary of vitamin-responsive early onset epileptic encephalopathy

2. Ohtahara syndrome

Ohtahara syndrome is often defined as an early infantile epileptic encephalopathy with a characteristic EEG pattern, suppression-burst, during which higher-voltage bursts of slow waves mixed with multifocal spikes alternate with isoelectric suppression phase28). EEG shows a continuous suppression-burst pattern in both waking and sleeping states. The onset is between neonatal period and early infancy, usually within the first 3 months of age, with some mothers reporting seizure-like movements of the fetus during pregnancy29). Etiologically, structural brain lesions, such as diffuse subependymal band heterotopia or midbrain dysplasia, are the most probable causes of Ohtahara syndrome30 31). Predominant seizures detected in Ohtahara syndrome patients are repetitive, frequent, tonic spasms occurring with or without series formation, although other seizure types can also be observed29 32). Antiepileptic and immunomodulating drugs are generally ineffective in treating tonic spasms, although rare cases show improvement upon such treatment. In general, prognosis is extremely poor with chronic intractable seizures and severe psychomotor retardation. Seizure patterns usually change with time: frequently cases evolve to West syndrome and further to Lennox-Gastaut syndrome with age. Nearly 50% of affected children are likely to die in infancy or childhood32 33).

3. Early myoclonic epileptic encephalopathy

Early myoclonic encephalopathy (EME) is characterized by fragmentary myoclonic jerks or violent myoclonic spasms, which generally occur in the neonatal period or early infancy. Partial myoclonus and partial motor seizures are the main seizure types in EME, but generalized myoclonus can also be observed in some patients. Partial motor seizures are frequent. They occur shortly after erratic myoclonus and shift typically from one part of the body to another in a random, asynchronous pattern34). The myoclonus usually involves the face or extremities, but may be restricted to some other part of the body. Typical interictal EEG shows a suppression-burst pattern similar to that seen in Ohtahara syndrome35). Suppression-bursts become more apparent in sleep and may persist until late childhood after a transient evolution to hypsarrhythmia in the middle to late infancy31). The generalized myoclonic jerk typically is associated with a generalized or fragmentary burst of polyspike, spike, and slow wave discharges, but erratic myoclonia may or may not be related to the bursts35). The etiology is variable and often remains unknown, but nonstructural/metabolic disorders are most probable causes of EME. Vitamin responsive epilepsies, such as PDE, pyridoxal-5-phosphate-dependent epilepsy, or folic acid responsive epilepsy can show typical clinical and EEG features of EME. Other inborn metabolic deficiencies, such as nonketotic hyperglycinemia, methylmalonic acidemia, or propionic acidemia, can also demonstrate EME features. Concentrations of serum amino acids and urine organic acids, as well as amino acid content of the CSF should be analyzed in patients with EME34 36). The prognosis for EME is also poor and there is no effective treatment except for vitamin responsive epilepsies. EME persists for long periods without evolution, except for the occasional transient phase of West syndrome, or changes into partial or severe epilepsy with multiple independent spike foci31).

4. Infantile spasms (West syndrome)

Infantile spasms or West syndrome is the most common epilepsy syndrome in infancy, which presents with a combination of the triad of infantile spasms, developmental deterioration, and hypsarrhythmic EEG pattern3 37). Typically, the spasms involve brief symmetrical contractions of musculature of the neck, trunk, and extremities, which frequently occur in clusters38 39). An individual spasm lasts for seconds (usual duration 1-2 seconds) and is often longer than typical myoclonus (duration up to 200 ms), though not as long as tonic seizures, which last for several seconds. Spasms are usually recurrent with a period of 5-30 seconds3 34). The spasms may be subtle and isolated at onset, typically clustering with time. Patients typically exhibit several clusters per day, particularly during drowsiness37 40). Hypsarrhythmia, a typical interictal EEG pattern observed in this condition, consists of a disorganized pattern with asynchronous, very high amplitude multifocal spike and sharp wave discharges. The etiology can be classified into symptomatic and cryptogenic cases. The fraction of symptomatic cases has been steadily increasing due to improved diagnostic techniques, such as metabolic and genetic testing, as well as neuroimaging41). Symptomatic causes are found in nearly 60% of cases, which include cerebral malformations, infection, hemorrhage, hypoxic-ischemic injury, metabolic disorders, and genetic conditions40 42). Tuberous sclerosis complex (TSC) is an important cause of infantile spasms and 75%-80% of individuals with TSC may develop epilepsy41). Outcomes are mostly dependent on the etiology; cryptogenic patients who are treated early have more favorable prognosis than patients with symptomatic varieties43 44).

5. Malignant migrating partial epilepsy in infancy

Malignant migrating partial epilepsy in infancy (MMPEI) is characterized by neonatal or early infantile onset migrating partial seizures, which usually last a few weeks or months, and the frequency becomes nearly continuous with time. Patients show frequent partial seizures of multifocal onset with autonomic manifestations, such as apnea, flushing, or cyanosis45). The interictal EEG shows multifocal epileptiform discharges with diffuse slowing of background activity. The multifocal discharges poorly activated by sleep in all cases and background activity slows down with fluctuating asymmetry between different recordings34). Most cases have no clear etiology of structural or biochemical abnormalities suggesting contribution of genetic factors. However, genetic tests usually fail to detect mutations in KCNQ2, KCNQ3, SCN1A, SCN2A, or CLCN2 genes in MMPEI46). Seizures are often intractable and global developmental delay is common. Most patients develop an acquired microcephaly by the end of the first year of age and a number of patients die before that time or later, in the course of the follow-up period45).

6. Myoclonic status in nonprogressive encephalopathies

Myoclonic status in nonprogressive encephalopathies (MSNE) is an early onset epileptic syndrome characterized by dulling of consciousness and responsiveness with or without jerks, which may last for hours, days, or weeks47). Interictal EEG consists of multifocal epileptiform discharges and background slowing. Ictal EEG recording may demonstrate generalized slow spike and wave or an absence pattern, depending on the seizure type34). A genetic cause, such as Angelman syndrome or 4p syndrome, is found in approximately half of the children. Other reported structural causes include hypoxic-ischemic injury and cortical dysplasia34). Most children are resistant to different therapies, even to intravenous benzodiazepines, and the status may become a life-threatening event47). Seizures often persist into adulthood and the final outcome is very poor with developmental regression and severe mental retardation, especially in patients with repeated episodes of myoclonic status48 49).

7. Dravet syndrome (severe myoclonic epilepsy in infancy)

Dravet syndrome is a genetically determined severe epileptic encephalopathy, which begins in the first year of life in an otherwise normal infant. The epilepsy starts with seizures, which may not initially differ from those associated with febrile illnesses. Even mild fever is an important trigger factor, but some cases are provoked by a nonfebrile illness, immunization, or hot environment50). It is not easy to differentiate these children from others with febrile convulsions, who will eventually get better and will not develop other types of seizures. During the second year of the life, seizures become more frequent, persistent, and often more lateralized. At that stage, seizures no longer occur only when a child has high temperature, but can happen at any time of the day34). Seizures are complex febrile, afebrile generalized, unilateral clonic, or tonic-clonic. The condition evolves to other types, such as myoclonic, atypical absence, complex partial seizures, and frequent status epilepticus50). EEG is usually normal at early stages of this condition. However, by the time a child is 2 years old, epileptic discharges with spike and wave or polyspikes are observed, which occur either as single events or in bursts. Prognosis is very poor, as this syndrome is associated with developmental delay, cognitive dysfunction, and behavioral problems.

Diagnostic approaches to underlying causes of EOEE

Diagnostic approaches to underlying causes of EOEE are summarized in Fig. 1. Assessments begin with the elucidation of the history and semiology of clinical seizures and analysis of EEG findings. When age onset, clinical manifestations, and EEG findings are consistent with EOEE, an evaluation of possible underlying etiologies should be performed. EOEE must be distinguished from acute symptomatic seizures occurring in infancy, for example, those caused by infection, hypoglycemia, or electrolyte disturbance3). If the primary investigations exclude precipitating conditions, a trial with the administration of a vitaminic compound (pyridoxine, pyridoxal-5-phosphate, or folinic acid) should then be initiated51 52). These new insights re-emphasize the importance of early treatment of neonatal seizures with vitamins, whatever the suspected cause. Pyridoxine, folic acid, and cyanocobalamin are still the most commonly prescribed treatments, largely due to their commercial availability and affordability. However, safer and more effective formulations can be obtained. Ideally, pyridoxal phosphate can be used instead of pyridoxine, but it is not licensed for sale or is not easily available in many countries. Direct purchasing biologically active vitamins overseas is possible through websites via internet searching. When importing 7 or more bottles of vitamins, import declaration and a medical prescription is necessary because vitamins are categorized as health functional foods in Korea. In the case of purchasing less than 7 bottles of Korean Ministry of Food and Drug Safety unrestrained vitamins for personal use, however, it is possible to pass customs without any prescriptions or declaration. Older children presenting with recurrent febrile status epilepticus or intractable seizures should receive similar therapy and, in addition, biotin in order to exclude biotinidase deficiency. If the patient responds to treatment, suitable biochemical and genetic investigations should then be undertaken to define the cause53). Clinicians should be aware that a poor response does not completely exclude diagnosis of vitamin dependent epilepsies51 54).

Fig. 1

Diagnostic approaches for the identification of the causes of early-onset epileptic encephalopathy. EOEE, early-onset epileptic encephalopathies; EEG, electroencephalogram.

During physical/neurologic examinations, certain clinical parameters, such as the combination of dysmorphic features, neurologic deficits, or cutaneous lesions, may at that point suggest underlying etiology. Following the completion of anamnesis, physical/neurologic examinations, EEG analysis, and magnetic resonance imaging of the brain, approximately two-thirds of patients will have an established etiologic diagnosis without the need to conduct extensive metabolic testing41). The remaining patients with undetermined etiologies should be considered for further evaluation, which will depend on individual circumstances. Typical tests may include organic acids in urine, amino acids in serum, determination of biotinidase, analyses of neurotransmitters, lactic acid, amino acids, folate metabolites, and glucose in the CSF as well as other biochemical tests suggested by the patient's clinical course and study findings41). Although they are relatively rare, metabolic encephalopathies are important to be recognized. Patients with some of these syndromes can respond to specific treatments, but some antiepileptic drugs interfering with metabolic pathways may worsen the clinical condition, so specific genetic counseling should be provided in such cases55). In a recent study, diagnostic genetic testing for childhood epileptic encephalopathy found genetic causes in 28% of the patients: 7% had inherited genetic metabolic disorders, while 21% had other genetic causes including genetic syndromes, pathogenic copy number variants (CNVs) revealed by comparative genomic hybridization arrays, and epileptic encephalopathy related to mutations in the SCN1A, SCN2A, SCN8A, KCNQ2, STXBP1, PCDH19, and SLC9A6 genes56). Genes mutated in early onset epileptic encephalopathy are summarized in Table 2. Targeted next-generation sequencing panels increased genetic diagnostic yield from less than 10% to over 25% in patients with epileptic encephalopathy56). Identification of mutations underlying cryptogenic EOEE needs to be performed in a targeted fashion by sequencing the most likely candidate genes. Massive parallel sequencing approaches enabled obtaining sequence information directly, however, the abundance of novel data, be it on the level of common single nucleotide polymorphisms, CNVs, or overall sequence, has led to the identification of a vast amount of benign variation in the human genome (Fig. 2)57). Massive parallel sequencing in epilepsy genetics can be divided into three different fields: family studies, gene panel studies, and patient-parents trio studies. Family studies are performed to identify the causal monogenic variant in families. Panel studies trade additional genetic information for deeper coverage outside the selected genes in contrast to exome sequencing studies. Patient-parent trio studies focus on the genome-wide identification of de novo mutations57).

Table 2

Summary of genes that are related to early onset epileptic encephalopathy

Fig. 2

The range of genetic variants predisposing to human disease by size. Adapted from Helbig I. Prog Brain Res 2014;213:253-7857), with permission of Elsevier B,V.

Conclusions

In conclusion, the diagnostic procedure for EOEE is still challenging, but early recognition and proper management have an important effect on its long-term outcomes. We believe that next-generation sequencing technologies are inspiring hope in a large number of children with cryptogenic encephalopathies and the use of these approaches will eventually lead to the development of new therapeutic strategies and, as a result, to more favorable long-term outcomes.

Acknowledgment

This study was supported by a grant of the Korea Health Technology R&D Project from the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C1234).

References

1. Engel J Jr. International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42:796–803. 11422340.

2. Nieh SE, Sherr EH. Epileptic encephalopathies: new genes and new pathways. Neurotherapeutics 2014;11:796–806. 25266964.

3. Alam S, Lux AL. Epilepsies in infancy. Arch Dis Child 2012;97:985–992. 22962318.

4. Nabbout R, Dulac O. Epileptic syndromes in infancy and childhood. Curr Opin Neurol 2008;21:161–166. 18317274.

5. Sharma S, Prasad AN. Genetic testing of epileptic encephalopathies of infancy: an approach. Can J Neurol Sci 2013;40:10–16. 23250121.

6. Guerrini R. Epilepsy in children. Lancet 2006;367:499–524. 16473127.

7. Nabbout R, Dulac O. Epileptic encephalopathies: a brief overview. J Clin Neurophysiol 2003;20:393–397. 14734929.

8. Lemke JR, Riesch E, Scheurenbrand T, Schubach M, Wilhelm C, Steiner I, et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia 2012;53:1387–1398. 22612257.

9. Epi4K Consortium. Epilepsy Phenome/Genome Project. Allen AS, Berkovic SF, Cossette P, Delanty N, et al. De novo mutations in epileptic encephalopathies. Nature 2013;501:217–221. 23934111.

10. Kearney JA. Epi4K phase I: gene discovery in epileptic encephalopathies by exome sequencing. Epilepsy Curr 2014;14:208–210. 25170321.

11. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 2012;485:237–241. 22495306.

12. Rauch A, Wieczorek D, Graf E, Wieland T, Endele S, Schwarzmayr T, et al. Range of genetic mutations associated with severe nonsyndromic sporadic intellectual disability: an exome sequencing study. Lancet 2012;380:1674–1682. 23020937.

13. Epi4K Consortium. Epi4K: gene discovery in 4,000 genomes. Epilepsia 2012;53:1457–1467. 22642626.

14. Baxter P. Recent insights into pre- and postnatal pyridoxal phosphate deficiency, a treatable metabolic encephalopathy. Dev Med Child Neurol 2010;52:597–598. 20586790.

15. Schmitt B, Baumgartner M, Mills PB, Clayton PT, Jakobs C, Keller E, et al. Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol 2010;52:e133–e142. 20370816.

16. Baxter P. Pyridoxine-dependent and pyridoxine-responsive seizures. Dev Med Child Neurol 2001;43:416–420. 11409832.

17. Baxter P. Pyridoxine or pyridoxal phosphate for intractable seizures? Arch Dis Child 2005;90:441–442. 15851419.

18. Agadi S, Quach MM, Haneef Z. Vitamin-responsive epileptic encephalopathies in children. Epilepsy Res Treat 2013;2013:510529. 23984056.

19. Surtees R, Wolf N. Treatable neonatal epilepsy. Arch Dis Child 2007;92:659–661. 17642476.

20. Wolf B, Heard GS, Weissbecker KA, McVoy JR, Grier RE, Leshner RT. Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol 1985;18:614–617. 4073853.

21. Salbert BA, Pellock JM, Wolf B. Characterization of seizures associated with biotinidase deficiency. Neurology 1993;43:1351–1355. 8327137.

22. Wolf B. The neurology of biotinidase deficiency. Mol Genet Metab 2011;104:27–34. 21696988.

23. Wolf B. Clinical issues and frequent questions about biotinidase deficiency. Mol Genet Metab 2010;100:6–13. 20129807.

24. Joshi SN, Fathalla M, Koul R, Maney MA, Bayoumi R. Biotin responsive seizures and encephalopathy due to biotinidase deficiency. Neurol India 2010;58:323–324. 20508364.

25. Lundgren J, Blennow G. Vitamin B12 deficiency may cause benign familial infantile convulsions: a case report. Acta Paediatr 1999;88:1158–1160. 10565467.

26. Erol I, Alehan F, Gumus A. West syndrome in an infant with vitamin B12 deficiency in the absence of macrocytic anaemia. Dev Med Child Neurol 2007;49:774–776. 17880648.

27. Rasmussen SA, Fernhoff PM, Scanlon KS. Vitamin B12 deficiency in children and adolescents. J Pediatr 2001;138:10–17. 11148506.

28. Ohtahara S, Yamatogi Y. Epileptic encephalopathies in early infancy with suppression-burst. J Clin Neurophysiol 2003;20:398–407. 14734930.

29. Zupanc ML. Clinical evaluation and diagnosis of severe epilepsy syndromes of early childhood. J Child Neurol 2009;24(8 Suppl):6S–14S. 19666878.

30. Ohtahara S, Ohtsuka Y, Yamatogi Y, Oka E. The early-infantile epileptic encephalopathy with suppression-burst: developmental aspects. Brain Dev 1987;9:371–376. 3434712.

31. Ohtahara S, Yamatogi Y. Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy. Epilepsy Res 2006;70(Suppl 1):S58–S67. 16829045.

32. Murakami N, Ohtsuka Y, Ohtahara S. Early infantile epileptic syndromes with suppression-bursts: early myoclonic encephalopathy vs. Ohtahara syndrome. Jpn J Psychiatry Neurol 1993;47:197–200. 8271543.

33. Fusco L, Pachatz C, Di Capua M, Vigevano F. Video/EEG aspects of early-infantile epileptic encephalopathy with suppression-bursts (Ohtahara syndrome). Brain Dev 2001;23:708–714. 11701283.

34. Khan S, Al Baradie R. Epileptic encephalopathies: an overview. Epilepsy Res Treat 2012;2012:403592. 23213494.

35. Lombroso CT. Early myoclonic encephalopathy, early infantile epileptic encephalopathy, and benign and severe infantile myoclonic epilepsies: a critical review and personal contributions. J Clin Neurophysiol 1990;7:380–408. 2120281.

36. Dalla Bernardina B, Dulac O, Fejerman N, Dravet C, Capovilla G, Bondavalli S, et al. Early myoclonic epileptic encephalopathy (E.M.E.E.). Eur J Pediatr 1983;140:248–252. 6414818.

37. Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004;62:1668–1681. 15159460.

38. Wong M, Trevathan E. Infantile spasms. Pediatr Neurol 2001;24:89–98. 11275456.

39. Trevathan E, Murphy CC, Yeargin-Allsopp M. The descriptive epidemiology of infantile spasms among Atlanta children. Epilepsia 1999;40:748–751. 10368073.

40. Caraballo R, Vaccarezza M, Cersosimo R, Rios V, Soraru A, Arroyo H, et al. Long-term follow-up of the ketogenic diet for refractory epilepsy: multicenter Argentinean experience in 216 pediatric patients. Seizure 2011;20:640–645. 21763159.

41. Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010;51:2175–2189. 20608959.

42. Vigevano F, Fusco L, Cusmai R, Claps D, Ricci S, Milani L. The idiopathic form of West syndrome. Epilepsia 1993;34:743–746. 8330587.

43. Lúthvígsson P, Olafsson E, Sigurthardottir S, Hauser WA. Epidemiologic features of infantile spasms in Iceland. Epilepsia 1994;35:802–805. 8082625.

44. Kivity S, Lerman P, Ariel R, Danziger Y, Mimouni M, Shinnar S. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 2004;45:255–262. 15009227.

45. Coppola G. Malignant migrating partial seizures in infancy: an epilepsy syndrome of unknown etiology. Epilepsia 2009;50(Suppl 5):49–51. 19469847.

46. Coppola G, Veggiotti P, Del Giudice EM, Bellini G, Longaretti F, Taglialatela M, et al. Mutational scanning of potassium, sodium and chloride ion channels in malignant migrating partial seizures in infancy. Brain Dev 2006;28:76–79. 16168594.

47. Elia M. Myoclonic status in nonprogressive encephalopathies: an update. Epilepsia 2009;50(Suppl 5):41–44. 19469845.

48. Dalla Bernardina B, Fontana E, Darra F. Myoclonic status in nonprogressive encephalopathies. Adv Neurol 2005;95:59–70. 15508914.

49. Caraballo RH, Cersosimo RO, Espeche A, Arroyo HA, Fejerman N. Myoclonic status in nonprogressive encephalopathies: study of 29 cases. Epilepsia 2007;48:107–113. 17241216.

50. Covanis A. Update on Dravet syndrome. Dev Med Child Neurol 2011;53(Suppl 2):v–vi. 21504423.

51. Bok LA, Maurits NM, Willemsen MA, Jakobs C, Teune LK, Poll-The BT, et al. The EEG response to pyridoxine-IV neither identifies nor excludes pyridoxine-dependent epilepsy. Epilepsia 2010;51:2406–2411. 20887371.

52. Bahi-Buisson N, Mention K, Leger PL, Valayanopoulos V, Nabbout R, Kaminska A, et al. Neonatal epilepsy and inborn errors of metabolism. Arch Pediatr 2006;13:284–292. 16343871.

53. Hoffmann GF, Schmitt B, Windfuhr M, Wagner N, Strehl H, Bagci S, et al. Pyridoxal 5'-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis 2007;30:96–99. 17216302.

54. Mills PB, Footitt EJ, Mills KA, Tuschl K, Aylett S, Varadkar S, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010;133(Pt 7):2148–2159. 20554659.

55. Sedel F, Gourfinkel-An I, Lyon-Caen O, Baulac M, Saudubray JM, Navarro V. Epilepsy and inborn errors of metabolism in adults: a diagnostic approach. J Inherit Metab Dis 2007;30:846–854. 17957491.

56. Mercimek-Mahmutoglu S, Patel J, Cordeiro D, Hewson S, Callen D, Donner EJ, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. Epilepsia 2015;56:707–716. 25818041.

57. Helbig I. New technologies in molecular genetics: the impact on epilepsy research. Prog Brain Res 2014;213:253–278. 25194493.

Article information Continued

(open-access, http://creativecommons.org/licenses/by-nc/3.0/) :

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Funded by : Ministry of Health and Welfarehttp://dx.doi.org/10.13039/501100003625

Award ID : HI14C1234

Disorder	Type of seizures	Etiology	Initial treatment	Long-term treatments
Pyridoxine dependent epilepsy	Focal or generalized, myoclonic, epileptic spasms	ALDH7A1	Pyridoxine 100 mg or 30 mg/kg	Pyridoxine 5-15 mg/kg daily (or add 3-5 mg/kg of folinic acid on pyridoxine)
Pyridoxal-5-phosphate dependent epilepsy	Multifocal myoclonic-tonic	PNPO	Pyridoxal-5-phosphate 30 mg/kg	Pyridoxal-5-phosphate 10-15 mg/kg daily
Folinic acid responsive seizures	Epileptic spasms, myoclonicastatic, absence, generalized tonic clonic	ALDH7A1, SLC46A1, FOLR1, MTHFR, MTHFS	Folinic acid or 5-methyltetrahydrofolate 3-5 mg/kg	Folinic acid or 5-methyltetrahydrofolate 3-5 mg/kg daily
Biotinidase deficiency	Myoclnic, generalized tonic clonic, infantile spasms, partial seizures	BTD	Biotin 5-20 mg	Biotin 5-10 mg twice daily
Vitamin B12 deficiency	Epileptic spasms, focal or generalized	Dietary (maternal B12 deficiency), TCN2, MMAA, MMAB, MMACHC, MMA DHC, MTRR, LMBRD1, MTR, ABCD4	Hydroxocobalamin or cyanocobalamin 1 mg daily to weekly or methylcobalamin 1 mg daily	Hydroxocobalamin or cyanocobalamin 1 mg every 1-3 months or methylcobalamin 1 mg daily

Table 2

Summary of genes that are related to early onset epileptic encephalopathy

Types	Clinical manifestations	Genes	Locus	Protein function
EIEE1	Earlyinfantile epileptic encephalopathy 1 (OMIM number 308350)	ARX	Xp22.13	Transcriptional repressor and activator
	X-linked myoclonic seizures, spasticity, and intellectual disability syndrome (OMIM number 308350)
	Idiopathic infantile epileptic-dyskinetic encephalopathy (OMIM number 308350)
	Ohtahara syndrome (OMIM number 308350)
EIEE2	Early infantile epileptic encephalopathy 2 (OMIM number 300672)	CDKL5	Xp22	Serine-threonine kinase
EIEE3	Ohtahara syndrome (OMIM number 308350)	SLC25A22	11p15.5	Mithocondrial glutamate/Hþ symporter
EIEE3	Early infantile epileptic encephalopathy 3 (OMIM number 609304)	SLC25A22	11p15.5	Mithocondrial glutamate/Hþ symporter
EIEE4	Ohtahara syndrome (OMIM number 308350)	STXBP1	9q341	Modulator of synaptic vesicle release
EIEE4	Early infantile epileptic encephalopathy 4 (OMIM number 612164)	STXBP1	9q341	Modulator of synaptic vesicle release
EIEE5	Early infantile epileptic encephalopathy 5 (OMIM number 613477)	SPTAN1	9q33-q34	Cytoskeletal protein
EIEE6	Dravet syndrome (OMIM number 607208)	SCN1A	2q24.3	Subunit of a voltage-gated sodium channel
EIEE7	Early infantile epileptic encephalopathy 7 (OMIM number 613720)	KCNQ2	20q13.3
EIEE7	Benign familial neonatal seizures-1 (OMIM number 121200)	KCNQ2	20q13.3
EIEE8	Early infantile epileptic encephalopathy 8 (OMIM number 300607)	ARHGEF9	Xq11.1	Rho-like GTPase to regulate CDC42 and other genes
EIEE9	Early infantile epileptic encephalopathy 9 (OMIM number 300088)	PCDH19	Xq22	Adhesion protein
EIEE10	Early infantile epileptic encephalopathy 10 (OMIM number 613402)	PNKP	19q13.33	Enzyme involved in DNA repair
EIEE11	Early infantile epileptic encephalopathy 11 (OMIM number 613721)	SCN2A	2q24.3	Subunit of a voltage-gated sodium channel
EIEE11	Benign familial neonatal seizures-1 (OMIM number 607745)	SCN2A	2q24.3	Subunit of a voltage-gated sodium channel
EIEE12	Early infantile epileptic encephalopathy 12 (OMIM number 613722)	PLCB1	20p12	Plays an important role in the intracellular transduction of many extracellular signalsa
EIEE12	Malignant migrating partial epilepsy in infancy	PLCB1	20p12
EIEE13	Early infantile epileptic encephalopathy 13 (OMIM number 614558)	SCN8A	12q13.1	Subunit of a voltage-gated sodium channel
EIEE13	Malignant migrating partial epilepsy in infancy	SCN8A	12q13.1	Subunit of a voltage-gated sodium channel
EIEE14	Early infantile epileptic Encephalopathy 14 (OMIM number 614959)	KCNT1	9q34.3	Sodium-activated potassium channel subunit
EIEE14	Malignant migrating partial epilepsy in infancy	KCNT1	9q34.3	Sodium-activated potassium channel subunit
EIEE15	Early infantile epileptic encephalopathy 15 (OMIM number 615006)	ST3GAL3	1p34.1	Catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates
EIEE16	Early infantile epileptic encephalopathy 16 (OMIM number 615338)	TBC1D24	16p13.3	Interacts with GTPases
EIEE17	Early infantile epileptic encephalopathy 17 (OMIM number 615473)	GNAO1	16q13	Modulators or transducers in various transmembrane signaling systems
EIEE18	Early infantile epileptic encephalopathy 18 (OMIM number 615476)	SZT2	1p34.2	Localized to the peroxisome, and is implicated in resistance to oxidative stress
EIEE19	Early infantile epileptic encephalopathy 19 (OMIM number 615744)	GABRA1	5q34	Encodes a gamma-aminobutyric acid (GABA) receptor